Raymond James Trust N.A. Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Raymond James Trust N.A. reduced its holdings in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 8.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,177 shares of the company’s stock after selling 1,473 shares during the quarter. Raymond James Trust N.A.’s holdings in Zoetis were worth $2,609,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Capital International Investors lifted its position in shares of Zoetis by 1,448.1% during the first quarter. Capital International Investors now owns 5,307,487 shares of the company’s stock worth $1,000,939,000 after purchasing an additional 4,964,646 shares in the last quarter. Norges Bank acquired a new position in shares of Zoetis during the fourth quarter worth $1,067,881,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Zoetis by 171.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,326,448 shares of the company’s stock worth $627,335,000 after purchasing an additional 2,102,306 shares in the last quarter. Castleview Partners LLC acquired a new position in shares of Zoetis during the fourth quarter worth $6,000,000. Finally, BlackRock Inc. lifted its position in shares of Zoetis by 3.6% during the first quarter. BlackRock Inc. now owns 41,766,559 shares of the company’s stock worth $7,876,755,000 after purchasing an additional 1,450,749 shares in the last quarter. 91.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on ZTS. Stifel Nicolaus reduced their target price on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Piper Sandler began coverage on shares of Zoetis in a report on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. The Goldman Sachs Group cut their price target on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a report on Thursday, July 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $224.00.

Zoetis Stock Down 1.2 %

Shares of NYSE:ZTS opened at $149.46 on Friday. The stock has a market capitalization of $69.97 billion, a price-to-earnings ratio of 33.89, a price-to-earnings-growth ratio of 2.64 and a beta of 0.77. Zoetis Inc. has a 1-year low of $148.96 and a 1-year high of $249.27. The company’s fifty day moving average is $167.61 and its two-hundred day moving average is $173.54. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18.

Zoetis (NYSE:ZTSGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.03 billion. Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the company posted $1.19 earnings per share. Equities analysts anticipate that Zoetis Inc. will post 5.01 EPS for the current year.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the transaction, the executive vice president now owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Roxanne Lagano sold 2,167 shares of the company’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the transaction, the executive vice president now owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kristin C. Peck sold 311 shares of the company’s stock in a transaction dated Thursday, July 7th. The stock was sold at an average price of $180.00, for a total transaction of $55,980.00. Following the transaction, the chief executive officer now owns 39,743 shares of the company’s stock, valued at approximately $7,153,740. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,501 shares of company stock worth $2,949,073. Insiders own 0.12% of the company’s stock.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.